US Stock MarketDetailed Quotes

Lexicon Pharmaceuticals (LXRX)

Watchlist

2.300
+0.120+5.50%

Close Aug 21 16:00 ET

1.02BMarket Cap-14.38P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Lexicon Pharmaceuticals (LXRX) Income Statement

Quarterly·All

YOY

Hide blank lines

Currency: USD

2026/Q2

2026/Q1

2025/Q4

2025/Q3

2025/Q2

2025/Q1

2024/Q4

2024/Q3

2024/Q2

2024/Q1

2023/Q4

2023/Q3

2023/Q2

2023/Q1

2022/Q4

2022/Q3

2022/Q2

2022/Q1

2021/Q4

2021/Q3

Total Revenue as Reported

-97.60%692.00K

+1572.11%21.10M

-79.31%5.49M

+710.40%14.18M

+1652.64%28.87M

+11.68%1.26M

+3682.62%26.55M

+980.25%1.75M

+419.56%1.65M

+4608.33%1.13M

+2407.14%702.00K

+315.38%162.00K

+805.71%317.00K

-35.14%24.00K

+100.00%28.00K

+69.57%39.00K

-85.04%35.00K

+37.04%37.00K

-92.96%14.00K

-99.65%23.00K

Total Operating Revenue

-97.60%692.00K

+1572.11%21.10M

-79.31%5.49M

+710.40%14.18M

+1652.64%28.87M

+11.68%1.26M

+3682.62%26.55M

+980.25%1.75M

+419.56%1.65M

+4608.33%1.13M

+2407.14%702.00K

+315.38%162.00K

+805.71%317.00K

-35.14%24.00K

+100.00%28.00K

+69.57%39.00K

-85.04%35.00K

+37.04%37.00K

-92.96%14.00K

-99.65%23.00K

Cost of Revenue

+18.18%39.00K

+260.00%108.00K

-42.24%201.00K

-85.92%10.00K

-80.12%33.00K

-3.23%30.00K

+397.14%348.00K

+914.29%71.00K

+1975.00%166.00K

--31.00K

--70.00K

--7.00K

--8.00K

--0.00

----

Gross Profit

-97.74%653.00K

+1604.06%20.99M

-79.81%5.29M

+744.07%14.17M

+1846.86%28.83M

+12.10%1.23M

+4046.52%26.21M

+983.23%1.68M

+379.29%1.48M

+4479.17%1.10M

+2157.14%632.00K

+297.44%155.00K

+782.86%309.00K

--24.00K

--28.00K

--39.00K

--35.00K

----

Operating Expense

+8.35%27.19M

-18.29%21.99M

-65.95%20.07M

-59.68%26.36M

-55.84%25.10M

-42.04%26.91M

+24.43%58.94M

+31.31%65.37M

+27.58%56.84M

+48.98%46.43M

+56.30%47.37M

+115.21%49.79M

+85.30%44.55M

+33.09%31.17M

+19.58%30.31M

+0.65%23.13M

+32.15%24.04M

+12.23%23.42M

+241.38%25.34M

-55.92%22.99M

Selling and Admin Expenses

+4.28%9.75M

-20.45%9.23M

-72.85%8.76M

-80.80%7.60M

-76.14%9.35M

-63.79%11.61M

-1.07%32.26M

+22.85%39.59M

+30.61%39.19M

+67.50%32.06M

+99.69%32.61M

+156.25%32.23M

+180.82%30.01M

+125.42%19.14M

+84.59%16.33M

+72.22%12.58M

+34.65%10.69M

+2.83%8.49M

+37.53%8.85M

-39.13%7.30M

-General & Admin Expense

----

+67.50%32.06M

----

+125.42%19.14M

----

+72.22%12.58M

--10.69M

--8.49M

----

--7.30M

Research & Development

+10.77%17.44M

-16.64%12.76M

-57.60%11.32M

-27.24%18.76M

-10.75%15.75M

+6.48%15.30M

+80.77%26.69M

+46.83%25.78M

+21.33%17.64M

+19.51%14.37M

+5.62%14.76M

+66.32%17.56M

+8.87%14.54M

-19.43%12.03M

-15.28%13.98M

-32.68%10.56M

+30.21%13.36M

+18.38%14.93M

+1563.10%16.50M

-60.94%15.68M

Operating Profit

-810.39%-26.54M

+96.12%-996.00K

+54.85%-14.78M

+80.87%-12.19M

+106.75%3.74M

+43.35%-25.68M

+29.95%-32.74M

-28.33%-63.69M

-25.12%-55.35M

-45.57%-45.33M

-54.36%-46.74M

-114.90%-49.63M

-84.28%-44.24M

-33.20%-31.14M

-19.53%-30.28M

-0.58%-23.10M

-33.68%-24.01M

-12.19%-23.38M

-250.59%-25.33M

+50.24%-22.96M

Net Non-Operating Interest Income (Expense)

-83.06%-886.00K

-112.24%-47.00K

+27.11%-750.00K

+47.94%-582.00K

-125.14%-484.00K

+112.53%384.00K

+65.92%-1.03M

-25.06%-1.12M

+389.91%1.93M

-286.87%-3.06M

-1297.69%-3.02M

-206.16%-894.00K

-14.48%-664.00K

-725.00%-792.00K

+23.13%-216.00K

-82.50%-292.00K

-437.04%-580.00K

+19.33%-96.00K

-139.86%-281.00K

+95.81%-160.00K

Non-Operating Interest Income

-6.05%1.72M

-30.46%1.54M

-54.72%1.28M

-54.33%1.57M

-55.66%1.83M

+17.78%2.22M

+17.78%2.83M

+14.61%3.44M

+219.14%4.14M

+83.09%1.88M

+170.80%2.40M

+425.35%3.01M

+953.66%1.30M

+7250.00%1.03M

+6235.71%887.00K

+5100.00%572.00K

+101.64%123.00K

-70.83%14.00K

-98.40%14.00K

-96.35%11.00K

Non-Operating Interest Expense

+12.55%2.61M

-13.35%1.59M

-47.36%2.03M

-52.76%2.16M

+4.84%2.32M

-62.91%1.84M

-28.83%3.86M

+17.00%4.56M

+12.81%2.21M

+171.72%4.95M

+391.48%5.42M

+351.27%3.90M

+178.81%1.96M

+1555.45%1.82M

+273.90%1.10M

+405.26%864.00K

+315.98%703.00K

-34.13%110.00K

+73.53%295.00K

-95.85%171.00K

Other Income (Expense)

---4.35M

----

Special Income (Charges)

---4.35M

----

--0.00

----

-Less:Other Special Charges

--4.35M

----

Pretax Profit

-1077.09%-31.78M

+95.88%-1.04M

+54.01%-15.53M

+80.30%-12.77M

+106.09%3.25M

+47.73%-25.30M

+32.14%-33.77M

-28.28%-64.81M

-18.98%-53.43M

-51.55%-48.40M

-63.17%-49.76M

-116.04%-50.53M

-82.63%-44.90M

-36.03%-31.93M

-19.07%-30.49M

-1.15%-23.39M

-36.09%-24.59M

-12.01%-23.48M

-366.08%-25.61M

-127.99%-23.12M

Net Profit

-1077.09%-31.78M

+95.88%-1.04M

+54.01%-15.53M

+80.30%-12.77M

+106.09%3.25M

+47.73%-25.30M

+32.14%-33.77M

-28.28%-64.81M

-18.98%-53.43M

-51.55%-48.40M

-63.17%-49.76M

-116.04%-50.53M

-82.63%-44.90M

-36.03%-31.93M

-19.07%-30.49M

-1.15%-23.39M

-36.09%-24.59M

-12.01%-23.48M

-366.08%-25.61M

-127.99%-23.12M

Profit from Continuing Operations

-1077.09%-31.78M

+95.88%-1.04M

+54.01%-15.53M

+80.30%-12.77M

+106.09%3.25M

+47.73%-25.30M

+32.14%-33.77M

-28.28%-64.81M

-18.98%-53.43M

-51.55%-48.40M

-63.17%-49.76M

-116.04%-50.53M

-82.63%-44.90M

-36.03%-31.93M

-19.07%-30.49M

-1.15%-23.39M

-36.09%-24.59M

-12.01%-23.48M

-366.08%-25.61M

-127.99%-23.12M

Net Income to Parent Company

-1077.09%-31.78M

+95.88%-1.04M

+54.01%-15.53M

+80.30%-12.77M

+106.09%3.25M

+47.73%-25.30M

+32.14%-33.77M

-28.28%-64.81M

-18.98%-53.43M

-51.55%-48.40M

-63.17%-49.76M

-116.04%-50.53M

-82.63%-44.90M

-36.03%-31.93M

-19.07%-30.49M

-1.15%-23.39M

-36.09%-24.59M

-12.01%-23.48M

-366.08%-25.61M

-127.99%-23.12M

Net Income to Common Stockholders

-1077.09%-31.78M

+95.88%-1.04M

+54.01%-15.53M

+80.30%-12.77M

+106.09%3.25M

+47.73%-25.30M

+32.14%-33.77M

-28.28%-64.81M

-18.98%-53.43M

-51.55%-48.40M

-63.17%-49.76M

-116.04%-50.53M

-82.63%-44.90M

-36.03%-31.93M

-19.07%-30.49M

-1.15%-23.39M

-36.09%-24.59M

-12.01%-23.48M

-366.08%-25.61M

-127.99%-23.12M

Basic EPS

-800.00%-0.07

+100.00%0.00

+55.56%-0.04

+77.78%-0.04

+105.88%0.01

+65.00%-0.07

+55.00%-0.09

+14.29%-0.18

+22.73%-0.17

-17.65%-0.20

-25.00%-0.20

-61.54%-0.21

-37.50%-0.22

-6.25%-0.17

+5.88%-0.16

+18.75%-0.13

-23.08%-0.16

-6.67%-0.16

-325.00%-0.17

-120.78%-0.16

Diluted EPS

-800.00%-0.07

+100.00%0.00

+55.56%-0.04

+77.78%-0.04

+105.88%0.01

+65.00%-0.07

+55.00%-0.09

+14.29%-0.18

+22.73%-0.17

-17.65%-0.20

-25.00%-0.20

-61.54%-0.21

-37.50%-0.22

-6.25%-0.17

+5.88%-0.16

+18.75%-0.13

-23.08%-0.16

-6.67%-0.16

-325.00%-0.17

-122.54%-0.16

Deadline

Jun 30, 2026

Mar 31, 2026

Dec 31, 2025

Sep 30, 2025

Jun 30, 2025

Mar 31, 2025

Dec 31, 2024

Sep 30, 2024

Jun 30, 2024

Mar 31, 2024

Dec 31, 2023

Sep 30, 2023

Jun 30, 2023

Mar 31, 2023

Dec 31, 2022

Sep 30, 2022

Jun 30, 2022

Mar 31, 2022

Dec 31, 2021

Sep 30, 2021

Accounting Standard

US_GAAP

	2026/Q2	2026/Q1	2025/Q4	2025/Q3	2025/Q2	2025/Q1	2024/Q4	2024/Q3	2024/Q2	2024/Q1	2023/Q4	2023/Q3	2023/Q2	2023/Q1	2022/Q4	2022/Q3	2022/Q2	2022/Q1	2021/Q4	2021/Q3

No. Symbol 5D % Chg

Middle East conflict spreads to the stock market! How should investors respond?

Ahead of the market open, US Treasury Secretary Bessent indicated that the United States and Iran are poised to reach an agreement the follo Show More

牛牛課堂

Mar 4 17:09

Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.

牛牛課堂

Mar 18 18:18

Hormuz, Term Structure and USO: Navigating the Energy Storm